FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, may also be eligible for coverage
Expanding coverage would make these products more accessible to underserved populations, particularly those disproportionately affected by obesity and diabetes
& Nicholson, M
A required route of administration due to unique medical needs. However, adding non-essential ingredients like B12, L-carnitine and other non-tested ingredients, does not qualify as a documented clinical difference
PlexusDx semaglutide injections include B12 formulation options to reduce the fatigue some patients experience when starting GLP-1 therapy
If your priority is minimal GI disruption and you need predictable craving control for long workdays, a different agent or a slower titration may be a better fit